RS20120022A1 - Fulvestrant u dozi od 500 mg za lečenje uznapredovalog kancera dojke - Google Patents

Fulvestrant u dozi od 500 mg za lečenje uznapredovalog kancera dojke

Info

Publication number
RS20120022A1
RS20120022A1 RS20120022A RSP20120022A RS20120022A1 RS 20120022 A1 RS20120022 A1 RS 20120022A1 RS 20120022 A RS20120022 A RS 20120022A RS P20120022 A RSP20120022 A RS P20120022A RS 20120022 A1 RS20120022 A1 RS 20120022A1
Authority
RS
Serbia
Prior art keywords
fulvestrant
patients
treatment
breast cancer
use according
Prior art date
Application number
RS20120022A
Other languages
English (en)
Serbian (sr)
Inventor
Alan Webster
Isaiah William Dimery
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20120022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS20120022A1 publication Critical patent/RS20120022A1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20120022A 2009-07-27 2010-07-26 Fulvestrant u dozi od 500 mg za lečenje uznapredovalog kancera dojke RS20120022A1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803
PCT/GB2010/051228 WO2011012885A1 (en) 2009-07-27 2010-07-26 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer

Publications (1)

Publication Number Publication Date
RS20120022A1 true RS20120022A1 (sr) 2012-10-31

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120022A RS20120022A1 (sr) 2009-07-27 2010-07-26 Fulvestrant u dozi od 500 mg za lečenje uznapredovalog kancera dojke

Country Status (36)

Country Link
US (1) US20120214778A1 (enExample)
EP (1) EP2459199A1 (enExample)
JP (1) JP2013500324A (enExample)
KR (1) KR20120042843A (enExample)
AT (1) AT510868A2 (enExample)
AU (1) AU2010277373A1 (enExample)
BG (1) BG111123A (enExample)
BR (1) BR112012001837A2 (enExample)
CA (1) CA2768286A1 (enExample)
CL (1) CL2012000226A1 (enExample)
CZ (1) CZ201235A3 (enExample)
DE (1) DE112010003084T5 (enExample)
DK (1) DK201270089A (enExample)
EA (1) EA201200190A1 (enExample)
EC (1) ECSP12011629A (enExample)
EE (1) EE201200003A (enExample)
ES (1) ES2393323A1 (enExample)
FI (1) FI20125207L (enExample)
GB (2) GB0912999D0 (enExample)
HR (1) HRP20120084A2 (enExample)
HU (1) HUP1200203A3 (enExample)
IL (1) IL217527A0 (enExample)
IS (1) IS8994A (enExample)
LT (1) LT5953B (enExample)
MX (1) MX2012001282A (enExample)
NO (1) NO20120147A1 (enExample)
PE (1) PE20121177A1 (enExample)
PL (1) PL399129A1 (enExample)
RO (1) RO128705A2 (enExample)
RS (1) RS20120022A1 (enExample)
SE (1) SE1250155A1 (enExample)
SG (1) SG177586A1 (enExample)
SK (1) SK500052012A3 (enExample)
TR (1) TR201200950T1 (enExample)
WO (1) WO2011012885A1 (enExample)
ZA (1) ZA201201406B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP2017515873A (ja) * 2014-05-21 2017-06-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法
US20190147986A1 (en) * 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
EP3528818B1 (en) * 2016-10-21 2021-09-15 Crescita Therapeutics Inc. Pharmaceutical compositions
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
TR201200950T1 (tr) 2012-09-21
PL399129A1 (pl) 2012-11-19
PE20121177A1 (es) 2012-09-23
CZ201235A3 (cs) 2012-06-27
IL217527A0 (en) 2012-02-29
FI20125207A7 (fi) 2012-02-23
SE1250155A1 (sv) 2012-02-22
EA201200190A1 (ru) 2012-08-30
HRP20120084A2 (hr) 2012-04-30
ES2393323A1 (es) 2012-12-20
HUP1200203A3 (en) 2012-12-28
WO2011012885A9 (en) 2011-03-24
GB201201486D0 (en) 2012-03-14
LT5953B (lt) 2013-07-25
WO2011012885A1 (en) 2011-02-03
JP2013500324A (ja) 2013-01-07
GB0912999D0 (en) 2009-09-02
HUP1200203A1 (en) 2012-09-28
EP2459199A1 (en) 2012-06-06
IS8994A (is) 2012-02-24
SG177586A1 (en) 2012-02-28
AU2010277373A1 (en) 2012-02-09
DE112010003084T5 (de) 2012-09-06
BR112012001837A2 (pt) 2016-03-15
MX2012001282A (es) 2012-06-12
EE201200003A (et) 2012-04-16
KR20120042843A (ko) 2012-05-03
CA2768286A1 (en) 2011-02-03
GB2484050A (en) 2012-03-28
CL2012000226A1 (es) 2012-08-31
ECSP12011629A (es) 2012-02-29
SK500052012A3 (sk) 2012-04-03
LT2012006A (lt) 2013-03-25
US20120214778A1 (en) 2012-08-23
BG111123A (bg) 2012-10-31
ZA201201406B (en) 2013-08-28
RO128705A2 (ro) 2013-08-30
AT510868A2 (de) 2012-07-15
FI20125207L (fi) 2012-02-23
NO20120147A1 (no) 2012-04-03
DK201270089A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
Lu et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-and perimenopausal patients with HR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial
Li et al. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications
Sainsbury The development of endocrine therapy for women with breast cancer
Modugno et al. Hormone response in ovarian cancer: time to reconsider as a clinical target?
Croxtall et al. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women
Makar Hormone therapy in epithelial ovarian cancer.
Emons et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie
Wang et al. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer
RS20120022A1 (sr) Fulvestrant u dozi od 500 mg za lečenje uznapredovalog kancera dojke
Gadducci et al. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer
Fujiwara et al. Advances in treatment of alveolar soft part sarcoma: an updated review
NO329949B1 (no) Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft
Bastianelli et al. Pharmacodynamics of combined estrogen–progestin oral contraceptives: 4. Effects on uterine and cervical epithelia
EP4630002A1 (en) Cancer therapy with capivasertib and fulvestrant
Goldhirsch et al. Adjuvant chemotherapy in premenopausal patients: a more complicated form of oophorectomy?
AU2012100098A4 (en) Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
Aguiar et al. Anemia in Patients With Pituitary Adenomas: Prevalence and Correlation With Hypopituitarism
Milewicz et al. Progesterone but not estradiol 17β potentiates local GH secretions by hormone-dependent breast cancer explants. An in vitro study
Komaranchath Adjuvant Endocrine Therapy in Early Breast Cancer
CN101404988A (zh) 乳腺癌治疗方案
Darwish et al. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt
WO2025233516A1 (en) Method of increasing time to second progression and time to first subsequent chemotherapy
WO2024234056A1 (en) Treatment of breast tissue
CA3220751A1 (en) Methods of treating breast cancer
LaPensee Mechanisms of chemoresistance in breast cancer and liposarcoma